See the Glossary for more terms.
Table of Contents
Program Announcements (PAs)
Requests for Applications (RFAs)
Changes to PI, Institution, or Title
Contact your program officer after you get your summary statement, and read the following in Part 6. If Not Funded of the Strategy for NIH Funding:
Yes, NIH’s definition of a new investigator depends on whether you were awarded certain types of grants, not whether you applied. So you can continue applying for an R01 and still be considered a new investigator.
We discuss NIH’s definition further at How to Qualify for New and Early-Stage Investigator Status.
See New Investigator Advice for more details.
No. Because paylines may not change, we advise you not to wait for possible funding later in the year.
If you revise and resubmit, you can improve your application based on the feedback from the initial peer review and hopefully get a better percentile and likelihood of getting an award.
Contact your program officer for more advice and read Options if Your Application Isn't Funded in the Strategy for NIH Funding.
Yes, but revising and resubmitting may be a better option because you'll have an opportunity to address reviewer comments. We suggest you improve your application regardless of whether you send a new one or resubmit.
Speak to your program officer and consider all your options. Learn more in Options if Your Application Isn't Funded in the Strategy for NIH Funding.
No. The eRA Commons allows investigators to send one resubmission while the earlier application remains active, so NIAID can fund the earlier application if a resubmission receives a worse score.
Not usually. If your resubmission scores worse, we can still fund your previous application.
That said, our data show that you're much more likely to score better than worse. By addressing the issues raised in your summary statement you will increase the likelihood that your resubmission will fare even better than your first try.
Just remember that the summary statement isn't an exhaustive critique. Read more in What to Do if You Get Bad News in the Strategy for NIH Funding.
No. First determine whether your problems are fixable.
We have more on this topic in What to Do if You Get Bad News in the Strategy for NIH Funding.
Read What to Do if You Get Bad News in the Strategy for NIH Funding.
Unless you applied to a request for applications (RFA), you have the following options:
Some RFAs do not allow resubmissions. If your previous application responded to an RFA, read your funding opportunity announcement to confirm you may resubmit.
Talk to your program officer and learn more at Options if Your Application Isn't Funded in the Strategy for NIH Funding.
Yes. You must include an introduction to the Research Plan. For details, read How to Resubmit in the Strategy for NIH Funding.
For an example of a good introduction to a resubmission, look at the Research Plan from Dr. Adam Ratner's sample application.
Yes. Use your summary statement as feedback. For advice, read What to Do if You Get Bad News in the Strategy for NIH Funding.
You should address reviewers' concerns in both the Introduction and Research Strategy (or elsewhere if the reviewers had concerns). Many applicants use the Introduction to explain how their resubmission responds to the issues and criticism raised in the original application's summary statement and then address individual comments throughout the Research Strategy. While we recommend addressing comments one-by-one in the Introduction, that may not always be possible due to the one-page limit. Fortunately our recommendation is not an NIH requirement. If you're cramped for space, don't drop important details in favor of making space to address reviewer comments. Learn more by reading How to Resubmit in Strategy for NIH Funding.
Remember, responding to criticism usually means altering your approach to account for reviewer concerns rather than arguing that the criticism is misguided. Don't waste space insisting that you were right all along.
For advice that’s specific to your application’s critiques and how you might address them within the one-page limit, talk to your program officer.
Yes. Read Options if Your Application Isn't Funded in the Strategy for NIH Funding for tips.
You may request a study section in your application's PHS Assignment Request Form, as explained in Requesting an Institute and Study Section; however, a request for a special emphasis panel (SEP) is unlikely to be honored.
Typically, your application will be assigned to an SEP if:
Contact your scientific review officer (SRO) to discuss your options. SROs frequently recruit ad hoc reviewers with specialized expertise to fill scientific expertise gaps in a review panel.
Once. For advice on what to do if your one resubmission fails, read Options if Your Application Isn't Funded in the Strategy for NIH Funding.
After one resubmission, you must submit a new application or look for funding outside of NIH.
You may keep some, all, or none of your previous application. For details, read Options if Your Application Isn't Funded in the Strategy for NIH Funding.
You must send your resubmission within 37 months of the original application's receipt date, regardless of when you actually submitted your application. See the Application Resubmissions SOP for more information.
No. You submit an AIDS and AIDS-related application in time for the May 7, September 7 or January 7 due dates whether the application is new, a renewal, a resubmission, or a revision. Non-AIDS applications generally have different due dates for initial applications and resubmissions.
Go to the Standard Due Dates for Competing Applications for all NIH receipt dates.
Yes. For details, read Options if Your Application Isn't Funded in the Strategy for NIH Funding.
Yes, you may reuse letters of support if your application is substantially similar.
That said, we advise you to consider how old the letters are when deciding whether to do so. Reviewers likely won’t mind reused letters if the previous application was recent. However, if they’re more than six to eight months old, the reviewers will likely be concerned that the letters are outdated.
No. The two main reasons are: a summary statement is not an exhaustive critique of your application, and your new reviewers may not agree with your previous ones. For more information, see Assess Peer Review Results in the Strategy for NIH Funding.
For more on this topic and how to proceed, read Options if Your Application Isn't Funded in the Strategy for NIH Funding.
Yes, as long as the organization is not a Public Health Service agency (e.g., FDA, CDC, AHRQ). Learn more at Broaden Your Horizons in the Strategy for NIH Funding.
If your application is selected for funding, you must list it in the other support information you send us just-in-time. Keep in mind that the other organization may have a similar requirement. See Prepare Your Other Support Submission in the Strategy for NIH Funding.
Check the NIAID Funding Opportunities List to make sure your program announcement (PA) is still on the list. If it is, you can find the expiration date in the Guide notice. You can resubmit until that time unless NIAID decides to extend the PA.
If the PA is no longer open, talk to your program officer for advice.
Yes, you may resubmit your application to any active program announcement, program announcement with set-aside funds (PAS), or program announcement reviewed in an institute (PAR) as long as you meet the new announcement's eligibility criteria.
You have two possibilities.
If we reissue an RFA (with a new number) that allows resubmissions, you have the option of submitting it as a new application or a resubmission.
However, if an RFA is open for several years (the RFA number remains the same) and simply allows resubmissions, you must apply with a resubmission.
You can appeal an initial peer review you feel was seriously flawed, though we often recommend revising and resubmitting your application instead.
Read more in Should You Appeal? in the Strategy for NIH Funding.
No. You can appeal only for defects in the review procedure. See our Appeals of Scientific Review of Grant Applications SOP for a list of reasons you may appeal.
Yes, but you will need to withdraw your appeal. You cannot have an appeal and a resubmission in the system at the same time. See the Appeals of Scientific Review of Grant Applications SOP for details.
Changing PI, Institution, or Title
If I change institutions, can I resubmit an application that I sent from my previous institution?
Yes. However, you'll have to get a letter from the signing official at the former institution that confirms its willingness to relinquish its ability to submit the resubmission application, then submit that letter to the Division of Receipt and Referral at NIH’s Center for Scientific Review (CSR).
NIH has no official template for this letter, but you’ll want to make sure it’s written on official letterhead and includes the signing officer’s signature.
You may send it one of two ways:
Don’t use NIH’s Official Statement Relinquishing Interests and Right in a Public Health Service Research Grant, though you may borrow text. That form is for funded grants only.
You will also have to fill in the Change of Institution section of the PHS 398 Checklist Form when you apply, and since you're applying with a resubmission, make sure to use the ID number from the original application when you fill out the SF 424 Form.
Yes. According to the SF 424 Application Guide, you should choose a new title if your Specific Aims have significantly changed. Note this in your cover letter.
Otherwise, a resubmission should have the same title as the previous application.
Yes. You may assume the role of PI on another investigator's resubmission—just make sure you rewrite the application to reflect that you are now PI and get approval from your business office to make the change.
In your cover letter, explain why you took over as PI. If the switch is related to comments from the previous review, note that.
No. If you are a new or early-stage investigator, you still get those benefits—e.g., a higher payline—even if the original PI was an established investigator.
One caveat to consider: reviewers will question a senior investigator who swaps roles with a new investigator. Even if you are an outstanding scientist, such a move might raise concerns about the quality of the science, the significance of the project, and the original investigator's commitment to his or her work.
Allay those concerns by explaining the change in your cover letter, as noted above.
Yes, you may use the same title again. Be sure to mark it as new in the application forms and eliminate any references to the previous review or previous review comments.
Email email@example.com with the title of this page or its URL and your question or comment. We answer questions by email and post them here. Thanks for helping us clarify and expand our knowledge base.
Last Updated April 22, 2016
Last Reviewed May 23, 2014